- Home
- CJET vs INTS Comparison
CJET vs INTS Comparison
Compare CJET & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CJET
- INTS
- Stock Information
- Founded
- CJET 2009
- INTS 2012
- Country
- CJET China
- INTS United States
- Employees
- CJET N/A
- INTS N/A
- Industry
- CJET Auto Manufacturing
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- CJET Consumer Discretionary
- INTS Health Care
- Exchange
- CJET Nasdaq
- INTS Nasdaq
- Market Cap
- CJET 8.3M
- INTS 8.7M
- IPO Year
- CJET N/A
- INTS 2023
- Fundamental
- Price
- CJET $2.02
- INTS $0.50
- Analyst Decision
- CJET
- INTS Strong Buy
- Analyst Count
- CJET 0
- INTS 3
- Target Price
- CJET N/A
- INTS $8.50
- AVG Volume (30 Days)
- CJET 57.6K
- INTS 396.2K
- Earning Date
- CJET 06-26-2025
- INTS 05-13-2025
- Dividend Yield
- CJET N/A
- INTS N/A
- EPS Growth
- CJET N/A
- INTS N/A
- EPS
- CJET N/A
- INTS N/A
- Revenue
- CJET $10,275,000.00
- INTS N/A
- Revenue This Year
- CJET N/A
- INTS N/A
- Revenue Next Year
- CJET N/A
- INTS N/A
- P/E Ratio
- CJET N/A
- INTS N/A
- Revenue Growth
- CJET 31.31
- INTS N/A
- 52 Week Low
- CJET $1.09
- INTS $0.50
- 52 Week High
- CJET $23.94
- INTS $5.28
- Technical
- Relative Strength Index (RSI)
- CJET 54.40
- INTS 18.57
- Support Level
- CJET $1.69
- INTS $0.46
- Resistance Level
- CJET $2.44
- INTS $0.59
- Average True Range (ATR)
- CJET 0.25
- INTS 0.05
- MACD
- CJET 0.01
- INTS 0.02
- Stochastic Oscillator
- CJET 45.45
- INTS 21.14
About CJET Chijet Motor Company Inc.
Chijet Motor Co Inc is engaged in the research and development, production and sales of new energy vehicles. New energy vehicles refer to plug-in electric vehicles including battery electric vehicles, plug-in hybrid (PHEV) electric vehicles, and fuel cell electric vehicles. Its passenger vehicles include small cars, sedans, and sports utility vehicles, or SUVs, and commercial vehicles include light trucks and vans.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.